(Q40141842)

English

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

scientific article published on March 1, 1984

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1 reference

Europe PubMed Central

Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent (English)

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J. A. Sinkule

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6326063

28 September 2023

language of work or name

0 references

publication date

1 March 1984

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

full work available at URL

http://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1984.tb03318.x

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1875-9114.1984.tb03318.x

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

61-73

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Delayed pyridine nucleotide reoxidation induced by the anticancer agent VM-26 as measured in vivo and in situ by NADH microfluorimetry

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Etoposide (VP-16-213)

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Review of etoposide single-agent activity

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

A review of etoposide in patients with non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

VP 16-213 in acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Epipodophyllin derivative (VP 16-213) in treatment of solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V).

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

VP16-213 as a single agent in advanced testicular tumors

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

VP-16–213 salvage therapy for refractory germinal neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Etoposide for therapy-resistant testicular tumors.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

VM 26 and VP 16-213: a comparative analysis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Podophyllotoxin derivative VP 16-213

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

Combination chemotherapy of bronchogenic carcinoma. I. Non-oat cell

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1984.TB03318.X

21 January 2018

The biological effects and the chemical composition of podophyllin: a review

1

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

The chemistry of Podophyllum

2

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Condyloma accuminata

7

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

The Cytological Effects of Podophyllin

9

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Response of patients with advanced neoplasms to the intravenous administration of alpha-peltatin

12

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

14

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action

17

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

20

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Inhibition of NADH-linked respiration with the anti-cancer agent 4'-demethyl-epipodophyllotoxin thenylidene glucoside (VM-26)

26

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Antimetastasis effect of two derivatives of epiposophyllotoxin in mice

29

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia

33

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

37

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16-213), due to a local effect

40

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice

42

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

EPEG, a new antineoplastic epipodophyllotoxin

46

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer

50

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

VP-16-213 (etoposide): the mandrake root from Issyk-Kul

57

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Phase I trial of a new form of an oral administration of VP-16-213

59

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

64

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

65

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma

66

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

70

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide as single agent and in combination with cis-platinum for malignant lymphomas

73

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Evaluation of VP-16-213 in malignant lymphoma and melanoma

78

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide in the treatment of acute leukemia in adults

92

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

94

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide salvage therapy for refractory germ cell tumors: an update

96

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

97

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer

104

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide in the treatment of refractory breast cancer

105

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Phase II clinical trial of VP-16-213 in ovarian cancer

107

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

PHASE I clinical trial of an oral solution of VP-16-213

113

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin

117

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Phase II study of oral VP-16-213 in hepatocellular carcinoma

118

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study

119

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide alone and in combination with cyclophosphamide, adriamycin and cis-platinum in patients with Mo and Mi non-small-cell lung cancer

121

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma

123

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Intensive induction therapy for small cell carcinoma of the lung

128

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Non-Hodgkin's lymphomas. II. Single agent chemotherapy

132

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Cis-dichlorodiammineplatinum (II) (cis-platinum) and etoposide for patients with refractory lymphomas

134

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors

135

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells

136

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents

138

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Radiation recall associated with VP-16-213 therapy

139

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Enhanced radiation reaction following combination chemotherapy for small cell carcinoma of the lung, possibly secondary to VP16-213

140

1 reference

10.1002/J.1875-9114.1984.TB03318.X

https://api.crossref.org/works/10.1002/J.1875-9114.1984.TB03318.X

28 September 2023

Identifiers

10.1002/J.1875-9114.1984.TB03318.X

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40141842&oldid=1983462397"